Alpha Biopharma received NMPA approval for Zorifertinib Tablets , the worlds first EGFR-TKI for lung cancer with brain metastases.
RDHL Stock | USD 6.74 0.34 5.31% |
About 55% of Redhill Biopharma's institutional investors are presently thinking to get in. The analysis of overall sentiment of trading Redhill Biopharma stock suggests that some investors are interested at this time. Redhill Biopharma's investing sentiment shows overall attitude of investors towards Redhill Biopharma.
Redhill |
On November 20, 2024, the National Medical Products Administration announced on its official website that the NMPA approved the listing of Zorifertinib Hydrochloride Tablets , a Class 1 innovative drug, developed by Alpha Biopharma. This product is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer accompanied with epidermal growth factor receptor exon 19 deletion or exon 21 s
Read at finance.yahoo.com
Redhill Biopharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Redhill Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Redhill Biopharma Fundamental Analysis
We analyze Redhill Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Redhill Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Redhill Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Redhill Biopharma is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Redhill Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Redhill Biopharma stock to make a market-neutral strategy. Peer analysis of Redhill Biopharma could also be used in its relative valuation, which is a method of valuing Redhill Biopharma by comparing valuation metrics with similar companies.
Peers
Redhill Biopharma Related Equities
CPHI | China Pharma | 5.26 | ||||
PTPI | Petros Pharmaceuticals | 4.00 | ||||
SXTC | China SXT | 2.63 | ||||
COLL | Collegium Pharmaceutical | 1.37 | ||||
ORGO | Organogenesis Holdings | 1.26 | ||||
CPIX | Cumberland Pharmaceuticals | 0.92 | ||||
EVOK | Evoke Pharma | 1.32 | ||||
CYTH | Cyclo Therapeutics | 1.41 | ||||
AQST | Aquestive Therapeutics | 4.85 | ||||
TKNO | Alpha Teknova | 5.94 | ||||
LFCR | Lifecore Biomedical | 6.68 | ||||
PRFX | Painreform | 23.08 |
Check out Redhill Biopharma Hype Analysis, Redhill Biopharma Correlation and Redhill Biopharma Performance. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.